An original logigramme to make safe discharge and community reintegration for COVID-19 patients

J Prev Med Hyg. 2020 Oct 6;61(3):E313-E320. doi: 10.15167/2421-4248/jpmh2020.61.3.1597. eCollection 2020 Sep.

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the microorganism responsible for the aggressive Coronavirus Disease (COVID-19) pandemic. During the such pandemic, discharge and community reintegration of patients are critical phases in guaranteeing public health. A review of the international and Italian experiences that represent the best available evidence was carried out, mainly focusing on the precise allocation of tasks and related responsibilities. The report provides a proposal for a systematic management pathway dedicated to COVID-19 patients. The original result is a logigramme to guide health practitioners on discharge and community reintegration of COVID-19 patients. To standardize clinical attitudes helps in ensuring quality of care and patient safety, should be a core element even during a public health emergency. The logigramme suggests, after discharge, 14 days of further isolation with regular health monitoring and, finally, the execution of a nasopharyngeal swab for identification of SARS-CoV-2 viral RNA. Home-cared patients should be placed on 7 days of further isolation after at least 2 negative RT-PCR tests for respiratory tract samples (nasopharyngeal swab). The logigramme is already used in the Department of Prevention - Local Health Agency of Lecce (Apulia) but it will be updated according to the latest research findings.

Keywords: COVID-19; Community reintegration criteria; Safe discharge.

MeSH terms

  • Asymptomatic Diseases
  • Betacoronavirus
  • COVID-19
  • COVID-19 Testing
  • Clinical Laboratory Techniques
  • Convalescence
  • Coronavirus Infections* / diagnosis
  • Female
  • Humans
  • Italy
  • Male
  • Monitoring, Ambulatory*
  • Nasopharynx / virology
  • Pandemics*
  • Patient Discharge / standards*
  • Pneumonia, Viral*
  • Quarantine*
  • SARS-CoV-2
  • Time Factors